Chroma Medicine

Chroma Medicine

  • Founded: 2021
  • Location: Brookline, MA
  • Employee range: 50 - 200
  • Clinical stage: RD
  • Therapy area: Genetic diseases
  • Drug types: GEN
  • Lead product: Undisclosed
  • Product link:
  • Funding: $135M B Mar 2023; $125M A Nov 2021
  • Investors: Atlas Venture, RCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management

job board

Short description:

DNA modification therapy

Drug notes:

Contact us to add description:

Long description:

Chroma Medicine is developing epigenetic medicines to revolutionize the treatment of genetic diseases. Epigenetics refers to the diverse ways in which the expression of genes can be regulated. Chroma is exploiting these natural gatekeeper mechanisms of gene expression to develop genomic medicines without changing the sequence of DNA. Chroma’s programmable epigenetic editors can target a specific genomic loci of therapeutic interest and either silence or activate the gene. The epigenetic changes made are specific and durable offering the potential for single-dose medicines. Chroma’s programmable and modular platform positions them to many therapeutic possibilities for which they hope to cure patients suffering from serious illnesses.


Chroma Medicine
Next Generation Sequencing Co-Op (Northeastern Uni...
Boston, MA|20 days ago
Chroma Medicine
Bioassay Analytical Development Co-Op (Northeaster...
Boston, MA|26 days ago
Chroma Medicine
Cell & Molecular Biology Co-Op (Northeastern Unive...
Boston, MA|26 days ago
Chroma Medicine
Computational Biology Co-Op (Northeastern Universi...
Boston, MA|26 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy